These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18837675)

  • 41. Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events.
    Stewart WC; Garrison PM
    Arch Intern Med; 1998 Feb; 158(3):221-6. PubMed ID: 9472201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
    Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of long-term topical glaucoma medication on conjunctival impression cytology.
    Turaçli E; Budak K; Kaur A; Mizrak B; Ekinci C
    Int Ophthalmol; 1997; 21(1):27-33. PubMed ID: 9298420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conjunctival damage induced by long-term topical anti-glaucoma therapy.
    Broadway D; Hitchings R
    Acta Ophthalmol Scand; 1996 Feb; 74(1):97. PubMed ID: 8689495
    [No Abstract]   [Full Text] [Related]  

  • 45. Topical carbonic anhydrase inhibitors.
    Talluto DM; Wyse TB; Krupin T
    Curr Opin Ophthalmol; 1997 Apr; 8(2):2-6. PubMed ID: 10168353
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Mode of action, clinical profile and significance of beta-blockers in antiglaucoma therapy].
    Schlote T
    Klin Monbl Augenheilkd; 2013 Feb; 230(2):120-6. PubMed ID: 23430677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Co-prescribing of medications used to treat obstructive lung disease, congestive heart failure and depression among users of topical beta blockers: estimates from three US Veterans Affairs Medical Centers.
    Valuck RJ; Perlman JI; Anderson C; Wortman GI
    Pharmacoepidemiol Drug Saf; 2001; 10(6):511-6. PubMed ID: 11828833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
    Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
    J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.
    Stewart WC; Laibovitz R; Horwitz B; Stewart RH; Ritch R; Kottler M
    Arch Ophthalmol; 1996 Aug; 114(8):938-42. PubMed ID: 8694728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Minimizing systemic absorption of topically administered ophthalmic drugs.
    Urtti A; Salminen L
    Surv Ophthalmol; 1993; 37(6):435-56. PubMed ID: 8100087
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment of glaucoma with brimonidine (Alphagan 0.2%)].
    Detry-Morel M; Dutrieux C
    J Fr Ophtalmol; 2000 Oct; 23(8):763-8. PubMed ID: 11033496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topical glaucoma medications and cardiovascular risk in the elderly.
    Monane M; Bohn RL; Gurwitz JH; Glynn RJ; Choodnovskiy I; Avorn J
    Clin Pharmacol Ther; 1994 Jan; 55(1):76-83. PubMed ID: 7905370
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Topical adrenergic potentiators in primary open-angle glaucoma.
    Kitazawa Y
    Am J Ophthalmol; 1972 Oct; 74(4):588-93. PubMed ID: 4403873
    [No Abstract]   [Full Text] [Related]  

  • 54. Contact dermatitis due to levobunolol in eyedrops.
    Garcia F; Blanco J; Juste S; Garces MM; Alonso L; Marcos ML; Carretero P; Perez R
    Contact Dermatitis; 1997 Apr; 36(4):230. PubMed ID: 9165213
    [No Abstract]   [Full Text] [Related]  

  • 55. [Topical optical beta-adrenergic antagonists and quinidine--a risky combination].
    Pianka P; Lazar M; Geyer O
    Harefuah; 1998 Mar; 134(5):402-3. PubMed ID: 10909562
    [No Abstract]   [Full Text] [Related]  

  • 56. Systemic adverse effects of topical ophthalmic agents. Implications for older patients.
    Diamond JP
    Drugs Aging; 1997 Nov; 11(5):352-60. PubMed ID: 9359022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pleiotropic effects in local drug treatment for glaucoma].
    Erb C
    Klin Monbl Augenheilkd; 2013 Feb; 230(2):141-5. PubMed ID: 23430678
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glaucoma therapy may take your breath away.
    Diggory P; Franks WA
    Age Ageing; 1997 Mar; 26(2):63-7. PubMed ID: 9177660
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost analysis of glaucoma medications: a 3-year review.
    Vold SD; Riggs WL; Jackimiec J
    J Glaucoma; 2002 Aug; 11(4):354-8. PubMed ID: 12169974
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selectivity of site of action and systemic effects of topical alpha agonists.
    Robin AL; Burnstein Y
    Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.